| 11.45 1.6 (16.24%) | 06-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.64  |
1-year : | 15.93 |
| Resists | First : | 11.68 |
Second : | 13.64 |
| Pivot price | 9.34 |
|||
| Supports | First : | 9.41 |
Second : | 8.01 |
| MAs | MA(5) : | 10.01 |
MA(20) : | 9.52 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 77.7 |
D(3) : | 66.3 |
| RSI | RSI(14): 63.8 |
|||
| 52-week | High : | 16.5 | Low : | 7.9 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EIKN ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 11.7 - 11.74 | 11.74 - 11.79 |
| Low: | 9.74 - 9.78 | 9.78 - 9.83 |
| Close: | 11.36 - 11.45 | 11.45 - 11.53 |
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Mon, 01 Jun 2026
Eikon Therapeutics (EIKN) highlights EIK1001 NSCLC and EIK1003 solid tumor data at ASCO 2026 - Stock Titan
Mon, 30 Mar 2026
Eikon Therapeutics Completes Upsized IPO Raising $381 Million and Advances Key Clinical Trials in Oncology - Quiver Quantitative
Mon, 30 Mar 2026
After a $381M IPO, Eikon fully enrolls a stage 4 lung cancer study - Stock Titan
Thu, 05 Feb 2026
Eikon’s $381M raise represents largest biopharma IPO in two years - BioWorld News
Wed, 04 Feb 2026
EIKN SEC Filings - Eikon Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Wed, 04 Feb 2026
EIKN Stock Price, News & Analysis | Eikon Therapeutics - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 17.3 (%) |
| Held by Institutions | 64.2 (%) |
| Shares Short | 4,070 (K) |
| Shares Short P.Month | 3,390 (K) |
| EPS | -6.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.17 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -224 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -1.82 |
| PEG Ratio | 0 |
| Price to Book value | 1.12 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.77 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|